Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617492 | 0.94 | SLC6A2 (0.42) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL11161096 | 0.82 | AOC3 (0.52) | KDM4ELMNAAOC3 | |
| SCHEMBL8470355 | 0.80 | LMNA (0.41) | KDM4ELMNAGAAALDH1A1SLC6A2 | |
| SCHEMBL8948210 | 0.79 | AOC3 (0.52) | KDM4ELMNAAOC3 | |
| SCHEMBL7876564 | 0.77 | GABBR2 (0.53) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL10209754 | 0.75 | SLC6A2 (0.62) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL17770622 | 0.74 | HRH1 (0.48) | KDM4EADRA2ALMNASLC6A2SLC6A4 | |
| SCHEMBL641330 | 0.72 | CYP2C19 (0.38) | KDM4EADRA2ALMNASLC6A2SLC6A4 | |
| Acetic Acid SCHEMBL8940243 | 0.70 | ADRA2A (0.52) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL5043328 | 0.70 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206369-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-02 | — | — | US | claimed |
| EP-3285814-B1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-06-24 | — | — | EP | claimed |
| US-20200179541-A1 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS | Life Technologies Corporation | 2020-06-11 | — | — | US | claimed |
| EP-3634500-A1 | ULTRASMALL NANOPARTICLES LABELED WITH ZIRCONIUM-89 AND METHODS THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2020-04-15 | — | — | EP | claimed |
| US-20200101180-A1 | ULTRASMALL NANOPARTICLES LABELED WITH ZIRCONIUM-89 AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2020-04-02 | — | — | US | claimed |
| WO-2018217528-A1 | ULTRASMALL NANOPARTICLES LABELED WITH ZIRCONIUM-89 AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-11-29 | — | — | WO | claimed |
| US-20180140725-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-05-24 | — | — | US | claimed |
| US-20180078662-A1 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS | Life Technologies Corporation | 2018-03-22 | — | — | US | claimed |
| EP-3285814-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | Memorial Sloan-Kettering Cancer Center (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172146-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-10-27 | — | — | WO | claimed |
| WO-2014066733-A2 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS | Life Technologies Corporation (US) | 2014-05-01 | — | — | WO | claimed |
| US-7749485-B2 | Liposomal assembly for therapeutic and/or diagnostic use | BRACCO RESEARCH S.A. (CH) | 2010-07-06 | — | — | US | claimed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | claimed |
| EP-1750671-B1 | LIPOSOMAL ASSEMBLY FOR THERAPEUTIC AND/OR DIAGNOSTIC USE | BRACCO RESEARCH SA (CH) | 2008-10-15 | — | — | EP | claimed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | claimed |
| US-20070196284-A1 | Liposomal assembly for therapeutic and/or diagnostic use | BRACCO RESEARCH S.A. (CH) | 2007-08-23 | — | — | US | claimed |
| EP-1750671-A1 | LIPOSOMAL ASSEMBLY FOR THERAPEUTIC AND/OR DIAGNOSTIC USE | BRACCO RESEARCH S.A. (CH) | 2007-02-14 | — | — | EP | claimed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | claimed |
| US-6984373-B2 | Fibrin binding moieties useful as imaging agents | DYAX CORP. (US) | 2006-01-10 | — | — | US | claimed |
| WO-2005117832-A1 | LIPOSOMAL ASSEMBLY FOR THERAPEUTIC AND/OR DIAGNOSTIC USE | BRACCO RESEARCH SA (CH) | 2005-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179541-A1 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS | ENGASE, FUCA1, GUSB | KDM4E 4333/4885ADRA2A 4465/4885ADRA2C 3993/4885 |
| US-20180078662-A1 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS | ENGASE, FUCA1, GUSB | KDM4E 4333/4885ADRA2A 4465/4885ADRA2C 3993/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | KDM4E 3602/4885ADRA2A 1412/4885ADRA2C 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.